Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled
- PMID: 15485752
- DOI: 10.1016/j.amjhyper.2004.05.017
Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled
Abstract
Background: Although the relationship between body weight and blood pressure (BP) is well established, there is a lack of data regarding the impact of obesity on the prevalence of hypertension in primary care practice. The objective of this study was to assess the prevalence of hypertension and the diagnosis, treatment status, and control rates of hypertension in obese patients as compared to patients with normal weight.
Methods: A cross-sectional point prevalence study of 45,125 unselected consecutive primary care attendees was conducted in a representative nationwide sample of 1912 primary care physicians in Germany (HYDRA).
Results: Blood pressure levels were consistently higher in obese patients. Overall prevalence of hypertension (blood pressure >/=140/90 mm Hg or on antihypertensive medication) in normal weight patients was 34.3%, in overweight participants 60.6%, in grade 1 obesity 72.9%, in grade 2 obesity 77.1%, and in grade 3 obesity 74.1%. The odds ratio (OR) for good BP control (<140/90 mm Hg) in diagnosed and treated patients was 0.8 (95% confidence interval [CI] 0.7-0.9) in overweight patients, 0.6 (95% CI 0.6-0.7) in grade 1, 0.5 (95% CI 0.4-0.6) in grade 2, and 0.7 (95% CI 0.5-0.9) in grade 3 obese patients.
Conclusions: The increasing prevalence of hypertension in obese patients and the low control rates in overweight and obese patients document the challenge that hypertension control in obese patients imposes on the primary care physician. These results highlight the need for specific evidence-based guidelines for the pharmacologic management of obesity-related hypertension in primary practice.
Similar articles
-
Primary care survey of awareness and control of hypertension: a hospital-based study.Am J Ther. 2010 May-Jun;17(3):295-300. doi: 10.1097/MJT.0b013e3181bdc3f6. Am J Ther. 2010. PMID: 19918167
-
Prevalence of renal insufficiency in individuals with hypertension and obesity/overweight: the FATH study.J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S194-200. doi: 10.1681/ASN.2006080914. J Am Soc Nephrol. 2006. PMID: 17130261
-
[Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Aug;25(8):710-4. Zhonghua Liu Xing Bing Xue Za Zhi. 2004. PMID: 15555399 Chinese.
-
Obesity and hypertension: epidemiological aspects of the relationship.J Hum Hypertens. 1990 Aug;4(4):431-5. J Hum Hypertens. 1990. PMID: 2258890 Review.
-
Management of high blood pressure in children and adolescents.Cardiol Clin. 2010 Nov;28(4):597-607. doi: 10.1016/j.ccl.2010.07.004. Cardiol Clin. 2010. PMID: 20937444 Review.
Cited by
-
Personal attributes that influence the adequate management of hypertension and dyslipidemia in patients with type 2 diabetes. Results from the DIAB-CORE Cooperation.Cardiovasc Diabetol. 2012 Oct 5;11:120. doi: 10.1186/1475-2840-11-120. Cardiovasc Diabetol. 2012. PMID: 23035799 Free PMC article.
-
New class of agents for treatment of hypertension: focus on direct renin inhibition.Vasc Health Risk Manag. 2010 Oct 5;6:869-82. doi: 10.2147/VHRM.S4189. Vasc Health Risk Manag. 2010. PMID: 20957132 Free PMC article. Review.
-
Comparison of efficacy and safety between two different irbesartan, generic vs branded, in the treatment of Korean patients with mild-to-moderate hypertension: an 8-week, multicenter, randomized, open-label, Phase IV clinical study.Drug Des Devel Ther. 2018 Dec 19;12:4217-4229. doi: 10.2147/DDDT.S172046. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 30587918 Free PMC article. Clinical Trial.
-
Highlights of mechanisms and treatment of obesity-related hypertension.J Hum Hypertens. 2022 Sep;36(9):785-793. doi: 10.1038/s41371-021-00644-y. Epub 2022 Jan 10. J Hum Hypertens. 2022. PMID: 35001082 Review.
-
Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS).Cardiovasc Diabetol. 2008 Oct 15;7:31. doi: 10.1186/1475-2840-7-31. Cardiovasc Diabetol. 2008. PMID: 18922160 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical